
Athenex, Inc. – NASDAQ:ATNX
Athenex stock price monthly change
Athenex stock price quarterly change
Athenex stock price yearly change
Athenex key metrics
Market Cap | 2.33M |
Enterprise value | 19.77M |
P/E | -0.08 |
EV/Sales | 0.19 |
EV/EBITDA | -0.26 |
Price/Sales | 0.07 |
Price/Book | -1.20 |
PEG ratio | N/A |
EPS | -16.17 |
Revenue | 119.83M |
EBITDA | -71.93M |
Income | -102.88M |
Revenue Q/Q | 0.51% |
Revenue Y/Y | -0.28% |
Profit margin | -100.02% |
Oper. margin | -68.52% |
Gross margin | 25.94% |
EBIT margin | -68.52% |
EBITDA margin | -60.03% |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeAthenex stock price history
Athenex stock forecast
Athenex financial statements
Mar 2022 | 29.72M | -30.46M | -102.51% |
---|---|---|---|
Jun 2022 | 31.51M | -24.03M | -76.26% |
Sep 2022 | 33.53M | -19.61M | -58.5% |
Dec 2022 | 25.06M | -28.76M | -114.78% |
2023-05-15 | -2.23 | -4.8 |
---|
Mar 2022 | 236862000 | 216.06M | 91.22% |
---|---|---|---|
Jun 2022 | 221887000 | 239.29M | 107.85% |
Sep 2022 | 228350000 | 221.11M | 96.83% |
Dec 2022 | 204055000 | 204.05M | 100% |
Mar 2022 | -23.88M | 37.88M | -25.37M |
---|---|---|---|
Jun 2022 | -20.45M | 8.32M | 6.05M |
Sep 2022 | -16.27M | -810K | 20.78M |
Dec 2022 | -14.39M | 12.50M | 103K |
Athenex alternative data
Aug 2023 | 269 |
---|---|
Sep 2023 | 269 |
Oct 2023 | 269 |
Nov 2023 | 269 |
Dec 2023 | 269 |
Jan 2024 | 269 |
Feb 2024 | 269 |
Mar 2024 | 269 |
Apr 2024 | 269 |
May 2024 | 269 |
Jun 2024 | 269 |
Jul 2024 | 269 |
Athenex other data
Period | Buy | Sel |
---|---|---|
Sep 2021 | 50000 | 0 |
Oct 2021 | 10000 | 0 |
Nov 2021 | 62952 | 0 |
Aug 2022 | 20000 | 0 |
Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
---|---|---|---|---|---|---|---|
Option | ANNONI JOE officer: Chief Financial Officer | Restricted Stock Units | 625 | N/A | N/A | ||
Option | ANNONI JOE officer: Chief Financial Officer | Common Stock | 625 | N/A | N/A | ||
Option | COOK TIMOTHY DEVERE officer: Chief Business and Com.. | Common Stock | 2,250 | N/A | N/A | ||
Option | LANG DANIEL officer: Pres Cell Therapy, VP .. | Restricted Stock Units | 12,500 | N/A | N/A | ||
Option | LANG DANIEL officer: Pres Cell Therapy, VP .. | Common Stock | 12,500 | N/A | N/A | ||
Option | COOK TIMOTHY DEVERE officer: Chief Business and Com.. | Restricted Stock Units | 2,250 | N/A | N/A | ||
Purchase | LAU JOHNSON YIU NAM director, officer: CEO and Chai.. | Common Stock | 20,000 | $0.46 | $9,100 | ||
Option | KWAN RUDOLF officer: EVP, Chi.. | Restricted Stock Units | 17,500 | N/A | N/A | ||
Option | LAU JOHNSON YIU NAM director, officer: CEO and Chai.. | Restricted Stock Units | 37,500 | N/A | N/A | ||
Option | KWAN RUDOLF officer: EVP, Chi.. | Common Stock | 17,500 | N/A | N/A |
Patent |
---|
Application Filling date: 29 Sep 2021 Issue date: 26 May 2022 |
Application Filling date: 31 Aug 2021 Issue date: 21 Apr 2022 |
Application Filling date: 7 Oct 2021 Issue date: 7 Apr 2022 |
Application Filling date: 7 Oct 2021 Issue date: 7 Apr 2022 |
Application Filling date: 8 Dec 2020 Issue date: 11 Nov 2021 |
Application Filling date: 19 Jan 2021 Issue date: 19 Aug 2021 |
Application Filling date: 24 Aug 2020 Issue date: 15 Jul 2021 |
Application Filling date: 17 Mar 2021 Issue date: 1 Jul 2021 |
Application Filling date: 1 Mar 2021 Issue date: 1 Jul 2021 |
Grant Filling date: 26 Dec 2018 Issue date: 13 Apr 2021 |
Quarter | Transcript |
---|---|
Q3 2022 6 Nov 2022 | Q3 2022 Earnings Call Transcript |
Q2 2022 28 Jul 2022 | Q2 2022 Earnings Call Transcript |
Q1 2022 10 May 2022 | Q1 2022 Earnings Call Transcript |
Q4 2021 16 Mar 2022 | Q4 2021 Earnings Call Transcript |
Insider | Compensation |
---|---|
Mr. Jeffrey M. Yordon (1949) Chief Operating Officer & Pres of Athenex Pharmaceutical Division | $693,450 |
Dr. Rudolf Kwan M.D., M.B., B.S. (1953) Chief Medical Officer | $483,200 |
Dr. Yiu-Nam Lau M.B.B.S., M.D., F.R.C.P., Ph.D. (1960) Chairman & Chief Executive Officer | $480,750 |
-
When is Athenex's next earnings date?
Unfortunately, Athenex's (ATNX) next earnings date is currently unknown.
-
Does Athenex pay dividends?
No, Athenex does not pay dividends.
-
How much money does Athenex make?
Athenex has a market capitalization of 2.33M and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 14.44% to 102.82M US dollars. Athenex made a loss 98.98M US dollars in net income (profit) last year or -$4.8 on an earnings per share basis.
-
What is Athenex's stock symbol?
Athenex, Inc. is traded on the NASDAQ under the ticker symbol "ATNX".
-
What is Athenex's primary industry?
Company operates in the Healthcare sector and Drug Manufacturers - Specialty & Generic industry.
-
How do i buy shares of Athenex?
Shares of Athenex can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Athenex's key executives?
Athenex's management team includes the following people:
- Mr. Jeffrey M. Yordon Chief Operating Officer & Pres of Athenex Pharmaceutical Division(age: 76, pay: $693,450)
- Dr. Rudolf Kwan M.D., M.B., B.S. Chief Medical Officer(age: 72, pay: $483,200)
- Dr. Yiu-Nam Lau M.B.B.S., M.D., F.R.C.P., Ph.D. Chairman & Chief Executive Officer(age: 65, pay: $480,750)
-
How many employees does Athenex have?
As Jul 2024, Athenex employs 269 workers.
-
When Athenex went public?
Athenex, Inc. is publicly traded company for more then 8 years since IPO on 14 Jun 2017.
-
What is Athenex's official website?
The official website for Athenex is athenex.com.
-
Where are Athenex's headquarters?
Athenex is headquartered at Conventus Building, Buffalo, NY.
-
How can i contact Athenex?
Athenex's mailing address is Conventus Building, Buffalo, NY and company can be reached via phone at +7 164272950.
Athenex company profile:

Athenex, Inc.
athenex.comNASDAQ
269
Drug Manufacturers - Specialty & Generic
Healthcare
Athenex, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of cancer. It operates through three segments: Oncology Innovation Platform, Global Supply Chain Platform, and Commercial Platform. The company's Orascovery product candidates include Oral paclitaxel and encequidar, an oral dosage form, which is in Phase III trial for metastatic breast cancer, as well as various clinical studies in cutaneous angiosarcoma, advanced gastric cancer, and advanced solid malignancies. It also offers Src Kinase product candidates comprising Tirbanibulin ointments for actinic keratosis, skin cancers, and psoriasis. In addition, the company is developing KUR-501, an autologous product that is in a phase I clinical trial for treating children with relapsed-refractory (R/R) high risk neuroblastoma; KUR-502, an allogeneic product, which is in a phase I clinical trial for treating adults with R/R CD19 positive malignancies, including B cell lymphoma, acute lymphoblastic leukemia, and chronic lymphocytic leukemia; and KUR-503, an allogeneic product that is in preclinical development for advanced hepatocellular carcinomas, as well as TCRT-ESO-A2, an autologous T cell receptor (TCR)-T cell therapy that is in phase 1 clinical trial for solid tumors. Further, it is developing dual absorption enhancers to inhibit the P-gp transporter and the cytochrome p450 3A enzymes within the gastrointestinal tract; and has a portfolio of TCRs that recognize hotspot mutations in p53, KRAS, and EGFR genes for multiple tumors. The company was formerly known as Kinex Pharmaceuticals LLC and changed its name to Athenex, Inc. in August 2015. Athenex, Inc. was incorporated in 2003 and is headquartered in Buffalo, New York.
Buffalo, NY 14203
CIK: 0001300699
ISIN: US04685N1037
CUSIP: 04685N103